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The 90 kDa heat shock protein (Hsp90) is a molecular chaperone responsible for folding
proteins that are directly associated with cancer progression. Consequently, inhibition of the
Hsp90 protein folding machinery results in a combinatorial attack on numerous oncogenic
pathways. Seventeen small-molecule inhibitors of Hsp90 have entered clinical trials, all of
which bind the Hsp90 N-terminus and exhibit pan-inhibitory activity against all four Hsp90
isoforms. pan-Inhibition of Hsp90 appears to be detrimental as toxicities have been reported
alongside induction of the pro-survival heat shock response. The development of Hsp90
isoform-selective inhibitors represents an alternative approach towards the treatment of
cancer that may limit some of the detriments. Described herein is a structure-based approach
to design isoform-selective inhibitors of Hsp90β, which induces the degradation of select
Hsp90 clients without concomitant induction of Hsp90 levels. Together, these initial studies
support the development of Hsp90β-selective inhibitors as a method to overcome the det-
riments associated with pan-inhibition.
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The Hsp90 family of proteins consist of four isoforms.Hsp90β is constitutively expressed in the cytoplasm,Hsp90α is expressed in the cytosol in response to cellular
stress, Grp94 resides in the endoplasmic reticulum, and Trap-1 is
localized to the mitochondria1–3. Together, these molecular
chaperones are responsible for the conformational maturation,
activation, and/or trafficking of ~300 Hsp90-dependent sub-
strates4–9. Many of the proteins dependent upon Hsp90 are
essential to the growth and proliferation of cancer cells. In fact,
proteins associated with all 10 hallmarks of cancer are dependent
upon the Hsp90 protein folding machinery10. Consequently,
Hsp90 has emerged as a promising target for the development of
anti-cancer chemotherapeutics11–13.
Seventeen small molecule inhibitors of Hsp90 have entered
clinical trials, all of which exhibit pan Hsp90 inhibitory activity
against all four isoforms14–17. Many of the compounds have pro-
duced cardiotoxicity, gastrointestinal toxicity, and/or ocular toxicity
amongst other side effects18–22. Recent studies have determined that
maturation of the hERG channel is also Hsp90 dependent, and
specifically depends upon the Hsp90α isoform23. In addition, pan
Hsp90 inhibition induces the pro-survival heat shock response,
which leads to induction of Hsp27, Hsp40, Hsp70, and Hsp90,
requiring the escalation of doses to overcome increased Hsp90
expression24–26. Among all four isoforms, specific roles for Grp94
and the consequences of selective Grp94-inhibition have been
deconvoluted. Selective Grp94 inhibition has emerged as a pro-
mising approach for the treatment of glaucoma, multiple myeloma
and metastasis. Recently, Patel and co-workers showed that Grp94
inhibition represents a non-toxic approach to treat Her2 positive
cancers. Collectively, these findings highlight the advantages of
isoform-selective Hsp90 inhibition and warrant a better under-
standing played by the specific roles of individual isoforms.
Hydrolysis of ATP by the N-terminal nucleoside binding
pocket is required for the maturation of client protein substrates,
and all four Hsp90’s share >70% identity in this region and 21
out of the 29 residues are totally conserved and the remaining
8 share high similarity27–29. Consequently, the discovery of
isoform-selective inhibitors has been challenging30,31. Since
Grp94 exhibits the lowest similarity with other Hsp90 isoforms,
three scaffolds manifesting Grp94-selective inhibition were
recently reported32–34. However, Hsp90α and Hsp90β share
~95% identity in this binding site and only two amino acids differ
between these isoforms, making the development of Hsp90α- or
Hsp90β-selective inhibitors most challenging. Based on differ-
ences exhibited between these two amino acids in the Hsp90α and
Hsp90β crystal structures, perturbation of the conserved water
molecules that mediate interactions with inhibitory ligands were
carefully analyzed, and a scaffold was developed that selectively
inhibits the Hsp90β isoform with > 50-fold selectivity. The design
and development of an Hsp90β-selective N-terminal scaffold is
reported herein.
Results
A water-mediated network of hydrogen bonds. Sequence
alignment of the N-terminal ATP-binding domain of Hsp90α and
Hsp90β reveals that Hsp90β contains Ala52 and Leu91 residues
in lieu of Ser52 and Ile91, which are present in Hsp90α (Sup-
plementary Fig. 1). As shown in Fig. 1a, there is a water-mediated
network of hydrogen bonds that align at the bottom of the pocket
surrounding the resorcinol ring of radicicol bound to each Hsp90
isoform (Fig. 1c, d, and Supplementary Fig. 2). Similar to other
Hsp90 inhibitors, radicicol (Fig. 1b) exhibits pan-inhibitory
activity. Thr184 and Asp93 (numbered for Hsp90β) produce
hydrogen bonds with the carbonyl and 4-phenol of radicicol
through three conserved water molecules. Overlay of the Hsp90α
and Hsp90β co-crystal structures suggest these water molecules
play different roles in each isoform as a consequence of the
replacement of Ser52 with Ala52 in Hsp90β31. Therefore, mod-








































Hsp90α: 0.38 ± 0.27 μM
Hsp90β: 3.29 ± 0.057 μM
Fig. 1 A water-mediated network of hydrogen bonds. a Three conserved water molecules at the bottom of the N-terminal ATP-binding site. b Structure of
the known Hsp90 N-terminal inhibitor radicicol, which has been numbered for clarity. c Modeling of radicicol into the N-terminal ATP-binding site of
Hsp90α (PDB code: 2XAB), and d Hsp90β (PDB code: 1UYM)
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evaluate these subtle differences about the 3- and 4-positions of
the resorcinol ring, as substituents at the 4-position of the
resorcinol ring would create unfavorable steric interactions with
the bulkier side chains conserved in Hsp90α (Ser52, Ile91) Grp94
(Val147), and Trap-1 (Ile156) binding pockets (Supplementary
Fig. 2).
Structure-activity relationships. Initial investigations began with
compound 1 (Fig. 2a), which lacks the 4-phenol. Compound 1
(Supplementary Fig. 7) is derived from a known Hsp90 inhibitor
and its Hsp90 inhibitory activity was confirmed via a fluorescence
polarization assay (Kd = 1.63 μM for Hsp90β and 3.21 μM for
Hsp90α, ~2-fold selective)35,36. The 2-phenol and the amide
moiety of 1 mimic interactions manifested by the 2-phenol and
lactone moiety present in the natural product, radicicol. The 5-
isopropyl appendage serves to produce hydrophobic interactions
with Phe138 and Val186 (Supplementary Fig. 3). Based on this
data, substituents at the 4-position were investigated to determine
selectivity and affinity against Hsp90β in silico. The cyano-
methylene substituent was the first selected modification, and, as
shown in Fig. 2b, the 4-cyanomethylene (2) was proposed to bind
within the ATP-binding pocket of Hsp90β (green), but due to
unfavorable steric interactions would not bind Hsp90α
(magenta), Grp94, or Trap1 (Supplementary Fig. 4). Additionally,
the nitrile was predicted to displace one of the conserved water
molecules (water molecule A in Fig. 1a) in the binding pocket and
increase the entropy of binding, while simultaneously establishing
itself within the hydrogen bond network. Once prepared (Sup-
plementary Fig. 8), compound 2 was evaluated in a fluorescence
polarization assay to determine binding affinity37. Compound 2
exhibited a Kd of 2.27 and 0.97 μM against Hsp90α and
Hsp90β, respectively, reflecting a (~2.5) 3-fold selectivity for
Hsp90β. Additional derivatives of the 4-position were then
prepared and included the 4-methoxymethylene and 4-formyl
moieties (Fig. 3a). Introduction of the smaller 4-formyl group
(4) led to both improved selectivity and affinity for Hsp90β
(Kd = 310 nM versus 1.55 μM, ~4-fold selectivity); however, the
4-methoxymethylene-containing compound (3) did not bind
either Hsp90 isoform at 10 μM (Fig. 3a). The binding modes of 2
and 4 were revealed by solution of the co-crystal structures bound
to Hsp90β at 1.9 and 2.4 Å resolution, respectively. Examination
of the co-crystal structures revealed an alternative binding mode
for appendages at the 4-position, as the formyl and cyano-
methylene appendages adopted a conformation wherein these
moieties orient toward the back of the pocket, instead of
the predicted forward orientation (Fig. 2b). In fact, Asn46 shifted
0.6 Å to accommodate the back-pointing cyanomethylene group
(Fig. 2c, d), which established a new binding mode and resulted in
hydrogen bonding interactions between the nitrile and Asn46
upon displacement of the conserved water molecule, B. The
carbonyl of 4 bound in the expected conformation and produced
hydrogen bonding interactions with Asn46, while simultaneously
displacing conserved water molecule A (Fig. 3b).
While an increase in affinity was observed, modifications at the
4-position did not produce increased selectivity. Therefore,
substituents were introduced at the 3-position to probe the
subtle differences between Hsp90α (Ser52, Ile91) and Hsp90β
(Ala52, Leu91). Molecular modeling studies suggested that the
inclusion of a hydroxymethylene group at the 3-position would
enhance selectivity for Hsp90β (Fig. 4a), as the methylene and








































Hsp90α: 3.21 ± 0.43 μM







Fig. 2 Proposed binding modes and co-crystal structures of Hsp90β-selective molecules. a A new scaffold for Hsp90β-selective inhibition. b Overlay of 2
docked into Hsp90α (PDB code 1UYM, colored green) with Hsp90β (PDB code: 2XAB). c Co-crystal structure of 2 bound to Hsp90β. d Compound 2 in 2-D
binding mode. Movement of Asn46 allows for backward bending of nitrile; the previous position of Asn46 is represented in pink. Asn46 in co-crystal
structure of 2 is represented in blue
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with Ser52 and Ile91 in Hsp90α. Similarly, introduction of a
benzyl alcohol would produce unfavorable interactions with
Val148 and prohibit Grp94 binding (Supplementary Fig. 5).
Furthermore, the hydroxyl group could displace one or both
conserved water molecules in this region (water molecules A and
B in Fig. 1a) and provide an entropic driving force. Upon
preparation of 5 (Supplementary Fig. 10), it was evaluated in a
fluorescence polarization assay and found to manifest an
apparent Kd of 4.27 μM for Hsp90β. More importantly, it
manifested selectivity (>25-fold) over the other isoforms. The co-
crystal structure of 5 bound to Hsp90β was solved (Supplemen-
tary Fig. 6), which confirmed that the benzyl alcohol displaced
both conserved water molecules, A and B, and participated in
hydrogen bonding interactions with the backbone of Leu43.
Since flexibility associated with the hydroxymethylene group
present in 5 is entropically disfavored, a ring-constrained variant
was sought to minimize the entropic penalty, while simulta-
neously enhancing affinity. Using the co-crystal structure of 5
bound to Hsp90β, it was envisioned that the introduction of a
heterocyclic ring system that joined both the 3- and 4-positions of
the resorcinol ring in the form of benzoisoxazole would serve to
illicit the desired interactions, while continuing to displace both
of the conserved water molecules, A and B, as observed with 5
(Supplementary Fig. 6). Therefore, benzoisoxazole 6a and the
fluoroisoindoline analog 6b were synthesized (Supplementary
Figs. 11 and 12) and found to manifest an apparent Kd of 180 nM
against Hsp90β, while exhibiting ~50-fold selectivity over Hsp90α
and Grp94. The co-crystal structure of 6b confirmed our
hypothesis, as both water molecules A and B were displaced
upon binding (Fig. 4b).
In vitro evaluation. Once the Hsp90β-selective inhibitor, 6a and
herein referred to as KUNB31, was identified, cellular studies
commenced to evaluate the effect of Hsp90β inhibition on cancer
cell lines. The anti-proliferative activity manifested by KUNB31
was evaluated against the cancer cell lines NCI H23 (non-small
cell lung cancer), UC3 (bladder cancer), HT-29 (colon adeno-
carcinoma) cells, as well as non-cancerous HEK 293 (human
embryonic kidney) cells. KUNB31 manifested an IC50 of 6.74±
1.10 µM, 3.01± 0.56 µM, and 3.72± 0.34 µM against NCI H23,
UC3, and HT-29 cancer cell lines, respectively, while requiring
more than 100 µM against HEK-293 cells. NCI H23 and HT29
cells were then evaluated via Western blot analyses of known
Hsp90α- and Hsp90β-dependent client proteins following treat-
ment with KUNB31 for 24 h. Prior studies identified CXCR4 and
CDK-4/6 as Hsp90β-dependent client proteins, while the hERG
channel, Erk-5, c-Raf and survivin represent Hsp90α-dependent
substrates38,39.
Since Hsp90 inhibition induces the degradation of Hsp90-
dependent substrates via the ubiquitin-proteosome pathway, the
levels of both kinase and non-kinase Hsp90 clients were assessed
via Western blot analysis. Known Hsp90 clients EGFR, HER2,
CDK4, CDK6, CXCR4, Akt-1, c-Raf, Survivin, ERK-5 and Integrin
α2 were analyzed following the administration of KUNB31 to
HT29 (colon adenocarcinoma grade II) cells. After a 24-h
incubation with KUNB31, Hsp90β-dependent client proteins
were reduced at concentrations that mirrored the cellular IC50
value, clearly linking cell viability to Hsp90β inhibition (Fig. 5a).
In contrast, the level of Hsp90α-dependent clients, Raf-1, ERK-5,
and survivin remained unaffected until higher concentrations. No
client protein degradation was observed for the Grp94-dependent
client, Integrin α2. Levels of clients like HER-2 and EGFR, which
do not appear to be isoform dependent, decrease around 5 μM.
Interestingly, levels of both Hsf-1 and Hsp90 decreased, which
provides evidence that selective inhibition of Hsp90β does not
increase Hsp90 levels as observed with the pan-Hsp90 N-terminal
a
b
Hsp90α: 2.28 ± 0.12 μM
Modifications to the 4-position
Hsp90β: 0.97 ± 0.03 μM
Hsp90α: 1.22 ± 0.01 μM
Hsp90β: 0.35 ± 0.13 μM
Hsp90α: > 25 μM














Fig. 3 Modifications to the 4-position. a Modifications to the 4-position of
the resorcinol ring and the corresponding Kd values. b Co-crystal structure











X The first Hsp90β-isoform selective compound
6a: X=H
6b: X=F
Hsp90α: 9.55 + 1.08 μM
Hsp90β: 0.18 + 0.01 μM
Hsp90α: 18.17 + 0.25 μM
Hsp90β: 0.44 + 0.56 μM
















Hsp90β: 4.27 + 0.95 μM
Fig. 4 Identification of an Hsp90β-selective inhibitor. a Proposed binding of
5 to Hsp90α (magenta) and Hsp90β (green). b Apparent Kd of 6a and b
determined by fluorescence polarization and the co-crystal structure of 6b
bound to Hsp90β
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inhibitor, geldanamycin. However, levels of Hsp27 and Hsp70
were induced at higher concentrations.
Hsp90 inhibitors that have undergone clinical evaluation bind
the Hsp90 N-terminal ATP-binding pocket and exhibit pan-
inhibitory activity. Therefore, the development of Hsp90 isoform-
selective inhibitors represents a new paradigm for cancer
treatment and provides a mechanism by which isoform-
dependent substrates can be elucidated and then selectively
targeted for degradation. On-target toxicities that result from
pan-inhibition of Hsp90 are not well understood, but may be
overcome through inhibition of individual isoforms. Therefore,
the development of isoform-selective inhibitors such as those
disclosed herein can elucidate the roles played by each isoform as
well as identify isoform-dependent substrates that contribute to
various diseases while simultaneously diminishing the liabilities
associated with pan-inhibition. Since the development of isoform-
selective inhibitors of enzymes that are > 95% identical represents
one of the greatest challenges in modern medicinal chemistry, the
discovery of such compounds represents a significant advance-
ment and lays the foundation for new therapeutic opportunities.
Only a few successful examples of isoform selective inhibitors
have been reported in the literature and, generally, those rely
upon the presence of amino acids that contain nucleophilic side
chains40. In contrast, by utilizing co-crystal structures of the
known Hsp90 inhibitor, radicicol, bound to both Hsp90α and
Hsp90β, a platform was developed on which the first Hsp90β
isoform-selective inhibitor was rationally designed. Although only
two amino acids differ between Hsp90α and Hsp90β, perturba-
tion of the conserved water molecules that reside within this
region led to the discovery of a small molecule that selectively
inhibits the Hsp90β isoform. Compound KUNB31, which
manifests 50-fold selectivity for Hsp90β, also manifests selective
activity against cancer cells. The data presented herein provide
the first evidence that selective inhibition of Hsp90β alters the
heat shock response and prevents Hsp90 induction, which
represents a serious detriment associated with pan-inhibitors of
Hsp90. Furthermore, compound KUNB31 can be used to validate
isoform-selective inhibition as a viable approach toward cancer
treatment while enabling the identification of specific roles played
by Hsp90β in other diseases.
Traditional approaches to Hsp90 inhibition have relied upon
pan-inhibition of all four Hsp90 isoforms. In an effort to advance
new paradigms for Hsp90 inhibition, small-molecule inhibitors
that manifest selective inhibition against individual Hsp90
isoforms were sought. The first N-terminal isoform-selective
inhibitors of Hsp90β, particularly KUNB31, have been identified
and shown to exhibit low micromolar anti-proliferative activity.
Furthermore, compound KUNB31 induced the degradation of
select Hsp90β-dependent clients without concomitant induction
of Hsp90 levels, providing a distinct and alternative mechanism
for the treatment of cancer. In conclusion, the first Hsp90β N-
terminal isoform-selective inhibitor has been discovered and
preliminary biological studies indicate an opportunity to
circumvent some of the challenges associated with the pan-
Hsp90 inhibitors undergoing clinical evaluation.
Methods
Florescence polarization. Assay was performed in 96-well format in black, flat-
bottom plates (Santa Cruz Biotechnology) with a final volume of 100 μL. Twenty-












































Fig. 5 In vitro evaluation of KUNB31. a Anti-proliferation values of 6a in immortalized cancerous (NCI-H23, UC3, HT29) and noncancerous (HEK-293) cells.
b Representative Western blot analyses 24h after treatment with 6a in HT29 cells at concentrations of 1, 3, 5, 15 and 30 μM. Negative and positive controls
include DMSO (D) and geldanamycin (G) at 500 nM, respectively
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20 mM Na2MoO4, 2 mM DTT, 0.1 mg/mL BGG, and 0.01% NP-40) containing 6
nM FITC-GDA (fluorescent tracer, stock in DMSO and diluted in assay buffer) and
50 μL of assay buffer containing 10 nM of either Grp94 or Hsp90α were added to
each well. Compounds were tested in triplicate wells (1% DMSO final concentra-
tion). For each plate, wells containing buffer only (background), tracer in buffer
only (low polarization control), and protein and tracer in buffer with 1% DMSO
(high polarization control) were included. Plates were incubated at 4 °C with
rocking for 24 h. Polarization values (in mP units) were measured at 37 °C with an
excitation filter at 485 nm and an emission filter at 528 nm. Polarization values
were correlated to % tracer bound and compound concentrations. The con-
centration at which the tracer was 50% displaced by the inhibitor was determined
using Graphpad Prism.
Anti-proliferation assay for HEK-293, HT29 and NCI-H23 cells. Cells were
grown to confluence and seeded at 2000 cells/well/0.1 mL in a 96-well plate and
placed back in the incubator for 24 h. Compounds or vehicle were administered at
the desired concentrations (1% DMSO final concentration) and incubated for 72 h.
The percentage of viable cells was determined using the MTS/PMS cell prolifera-
tion kit (Promega) per the manufacturer’s instructions. Cells treated with vehicle
were normalized to 100% proliferation and values adjusted accordingly.
HT29 (ATCC® HTB-38™) cells are human colorectal adenocarcinoma isolated
from a 44-year-old, female, Caucasian patient and purchased from ATCC in April
2016. NCI-HT23 (ATCC® CRL-5800™) are non-small-cell, human lung
adenocarcinoma isolated from a 51-year-old, male, Black patient and purchased
from ATCC in April 2016. No characterization or mycoplasma testing was
conducted on these cell lines following their purchase.
Anti-proliferation assay for UM-UC-3 cells. UM-UC-3 cells were grown to
confluence and seeded at 2000 cells/well/0.1 mL in a 96-well plate and placed back
in the incubator for 24 h. Compounds or vehicle was administered at the desired
concentrations (1% DMSO final concentration) and incubated for 72 h. The per-
centage of viable cells was determined using the Cell-Titer-Glo Luminescent Cell
Viability Kit (Promega) per the manufacturer’s instructions. Cells treated with
vehicle were normalized to 100% proliferation and values adjusted accordingly.
UM-UC-3 cells (ATCC® CRL-1749™) are bladder adenocarcinoma isolated
from a male patient. No characterization or mycoplasma testing was conducted on
these cell lines following their purchase.
Western blot for UM-UC-3 cells. UM-UC-3 cells were harvested in cold PBS and
lysed with RIPA buffer: 50 mM Tris-HCl pH 7.5, 150 mM NaCl, containing 0.1%
SDS, 1% Igepal, 1% sodium deoxycholate, protease and phosphatase inhibitor
cocktail (Sigma-Aldrich, Inc., St. Louis, MO) by three freeze-thaw cycles using
liquid nitrogen and a 37 °C water bath. Protein concentration was determined
using DC Protein Assay (Bio-Rad Laboratories, Hercules, CA). Equal amounts of
protein (20 μg) were loaded on a Novex E-PAGETM 8% protein gel (Life Tech-
nologies), transferred to a nitrocellulose membrane by Novex iBlotR Gel Transfer
system (Invitrogen, Carlsbad, CA), blocked in TBS-T containing 5% milk, and
probed with primary antibodies (1:1000 dilution). Membranes were incubated with
a horseradish peroxidase-conjugated secondary antibody, developed and visualized
with Li-COR Odyssey Image system. All Western blots were probed for the loading
control β-actin.
Western blot for NCI-H23 cells. The NCI-H23 cells were harvested in cold PBS
and lysed with mammalian protein extraction reagent (MPER, Pierce) lysis buffer
containing protease and phosphatase inhibitors (Roche) on ice for 1 h. Lysates were
clarified at 15,000 g for 20 min at 4 °C. Protein concentrations were determined
using the Qubit protein quantification assay kit per the manufacturer’s instructions
(ThermoFisher). Equal amounts of protein (2.5–20 μg) were electrophoresed under
reducing conditions (10% acrylamide gel), transferred to a polyvinylidene fluoride
membrane (PVDF), and immunoblotted with the corresponding specific anti-
bodies. Membranes were incubated with an appropriate horseradish peroxidase-
labeled secondary antibody, developed with a chemiluminescent substrate, and
visualized. Data were first converted to 8-bit images in ImageJ, then Image Studio
Lite Ver. 5.2 or Li-COR Odyssey Image Studio Ver 4.0 was used to perform
densitometry. All proteins were normalized to actin and then DMSO, and the
relative densities were reported.
Co-crystal structure. His6-tagged human Hsp90β N-terminal domain (amino
acids 1–218) was cloned into a modified pET vector, over-expressed in Escherichia
coli BL21 DE3 cells and purified by Ni-NTA chromatography. The tag was cleaved
using TEV protease, followed by a second subtracting Ni-NTA chromatography to
remove the TEV and the his-tag moiety. The flow-through containing the cleaved
protein was then concentrated and further purified via Superdex 200 size exclusion
chromatography in 20 mM Tris-HCl, 150 mM NaCl, pH 7.8. Protein-inhibitor
complexes were formed by mixing 15 mg/mL of Hsp90β NT with each inhibitor, at
1.5–2.0 mM final drug concentrations, and incubating at 4 °C for 1 h. Co-
crystallization drops were set up at room temperature using 1:1 protein/drug to
reservoir buffer of 30% PEG 8,000, 0.2 M sodium acetate, and 0.1 sodium caco-
dylate pH 6.5. Crystals appeared in 1–2 days and were harvested in a cryo-buffer
containing 20% glycerol added to the reservoir buffer with each respective inhibitor
at 2 mM.
Co-crystal structure determination. Data collection was done at the beamline 19-
ID at the Advanced Photon Source (APS), Argonne National Laboratory. The
structure was solved by molecular replacement method using Phaser (28) with the
structure of Hsp90-beta (PDB code 1UYM) as the model template. PHENIX
program (29) was used for the refinement, and Coot (30) was used for the iterative
manual model building. Translation, libration and screw-rotation displacement
(TLS) groups used in the refinement were defined by the TLMSD server (31). The
current models are of good geometry and refinement statistics (Supplementary
Table 1). All structure factors and pdbs were deposited with RCSB.org with pdb
accession codes 5UC4, 5UCH, 5UCI and 5UCJ.
X-ray crystallography study for C19H18N2O3, v87c(1). A set of unique dif-
fraction data (4438 0.5°-wide ω- or ϕ-scan frames with scan times of 3–6 s) were
collected (Supplementary Fig. 1) at 100(2)K for a single-domain crystal using
monochromated CuKa radiation (l = 1.54178 Å) on a Bruker Proteum Single
Crystal Diffraction System equipped with dual CCD area detectors. Data collection
utilized a Platinum 135 CCD detector with a crystal-to-detector distance of 8.0 cm
and Helios high-brilliance multilayer optics. X-rays were provided with a Bruker
MicroStar microfocus Cu rotating anode X-ray source operating at 45 kV and 60
mA. The integrated data (Supplementary Fig. 2) were corrected empirically for
variable absorption effects using equivalent reflections. The Bruker software
package SHELXTL was used to solve the structure using “direct methods” tech-
niques. All stages of weighted full-matrix least-squares refinement were conducted
using Fo2 data with the SHELXTL XL v2014 software package (Supplementary
Fig. 3). All hydrogen atoms were located from a difference Fourier and refined in
least-square refinement cycles as independent isotropic atoms. All non-hydrogen
atoms were included in the structural model with anisotropic thermal parameters.
Final crystallographic details are summarized in Supplementary Table 1.
Data availability. The data that support the findings of this study are available
from the corresponding author upon reasonable request. All structure factors and
PDBs were deposited with RCSB.org with PDB accession codes 5UC4, 5UCH,
5UCI and 5UCJ.
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